- Home
- PEN vs ELAN Comparison
PEN vs ELAN Comparison
Compare PEN & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEN
- ELAN
- Stock Information
- Founded
- PEN 2004
- ELAN 1954
- Country
- PEN United States
- ELAN United States
- Employees
- PEN N/A
- ELAN N/A
- Industry
- PEN Medical/Dental Instruments
- ELAN Biotechnology: Pharmaceutical Preparations
- Sector
- PEN Health Care
- ELAN Health Care
- Exchange
- PEN Nasdaq
- ELAN Nasdaq
- Market Cap
- PEN 7.0B
- ELAN 6.3B
- IPO Year
- PEN 2015
- ELAN 2018
- Fundamental
- Price
- PEN $244.98
- ELAN $13.35
- Analyst Decision
- PEN Buy
- ELAN Buy
- Analyst Count
- PEN 14
- ELAN 6
- Target Price
- PEN $232.23
- ELAN $17.00
- AVG Volume (30 Days)
- PEN 420.1K
- ELAN 4.6M
- Earning Date
- PEN 10-30-2024
- ELAN 11-07-2024
- Dividend Yield
- PEN N/A
- ELAN N/A
- EPS Growth
- PEN N/A
- ELAN N/A
- EPS
- PEN 0.89
- ELAN 0.41
- Revenue
- PEN $1,163,776,000.00
- ELAN $4,454,000,000.00
- Revenue This Year
- PEN $13.65
- ELAN $2.22
- Revenue Next Year
- PEN $14.38
- ELAN $2.77
- P/E Ratio
- PEN $276.50
- ELAN $32.38
- Revenue Growth
- PEN 16.96
- ELAN 1.99
- 52 Week Low
- PEN $148.00
- ELAN $11.40
- 52 Week High
- PEN $277.34
- ELAN $18.80
- Technical
- Relative Strength Index (RSI)
- PEN 69.88
- ELAN 46.92
- Support Level
- PEN $234.62
- ELAN $13.15
- Resistance Level
- PEN $242.95
- ELAN $13.58
- Average True Range (ATR)
- PEN 6.39
- ELAN 0.51
- MACD
- PEN -0.13
- ELAN 0.00
- Stochastic Oscillator
- PEN 98.61
- ELAN 41.67
About PEN Penumbra Inc.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
About ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.